

Preliminary Amendment
Serial No. 09/003,869
Page 3 of 6

34. (Once Amended) The pharmaceutical composition according to any one of claims 23-28, further comprising a therapeutically effect amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.

REMARKS

Applicants appreciate the Examiner's acknowledgment that claims 1-15 and 23-30 are allowable. The amendments presented herewith, while not made for reasons related to patentability, are believed to place all claims in condition for allowance. In accordance with 37 C.F.R. §1.121, a marked up copy of the amended claims is attached hereto. Additions are noted by underlining. Deletions are noted by bracketing. Support for the amendments can be found, for example, in the originally filed claims.

CONCLUSION

Notification of allowance of all claims is respectfully requested. Furthermore, Applicants via U.S. mail during the week of January 27, 2002, will file a Supplemental Information Disclosure Statement and PTO/SB/08A with references. Applicants also respectfully request return of an initialed copy of the Form PTO/SB/08A (4 pages) attached to the Information Disclosure Statement

Preliminary Amendment
Serial No. 09/003,869
Page 4 of 6

mailed on August 1, 2001. The Examiner is also invited to contact Applicants' undersigned representative if it is believed that prosecution may be furthered thereby.

Respectfully submitted,

Beeley et al.

Dated: 23 Jan 02

By: 

Bradford J. Duft
Reg. No. 32,219

BROBECK, PHLEGER & HARRISON LLP
12390 El Camino Real
San Diego, CA 92130
Phone (858) 720-2584
Fax (858) 720-2555

Preliminary Amendment
Serial No. 09/003,869
Page 5 of 6

MARKED UP VERSION OF AMENDED CLAIMS

16. (Twice Amended) The method according to any one of claims [1-14 or 15] 1-15 wherein said exendin is exendin-3.

17. (Twice Amended) The method according to any one of claims [1-14 or 15] 1-15 wherein said exendin is exendin-4.

18. (Twice Amended) The method according to any one of claims [1-14 or 15] 1-15 wherein said exendin agonist is selected from the group consisting of exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, ¹⁴Leu, ²⁵Phe exendin-4 amide, ¹⁴Leu, ²⁵Phe exendin-4 (1-28) amide, and ¹⁴Leu, ²²Ala, ²⁵Phe exendin-4 (1-28) amide.

19. (Twice Amended) The method according to any one of claims [1-14 or 15] 1-15, further comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.

20. (Twice Amended) The method according to any one of claims [1-14 or 15] 1-15 wherein said exendin agonist is an exendin agonist according to Formula I.

21. (Twice Amended) The method according to any one of claims [1-14 or 15] 1-15 wherein said exendin agonist is an exendin agonist according to Formula II.

22. (Twice Amended) The method according to any one of claims [1-14 or 15] 1-15 wherein said exendin agonist is an exendin agonist according to Formula III.

32. (Once Amended) The method according to any one of claims [1-14 or 15] 1-15 wherein said exendin agonist is an exendin agonist according to Formula II, and wherein said method further

Preliminary Amendment
Serial No. 09/003,869
Page 6 of 6

comprises administering to said subject a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.

33. (Once Amended) The method according to any one of claims [1-14 or 15] 1-15 wherein said exendin agonist is an exendin agonist according to Formula III, and wherein said method further comprises administering to said subject a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.

34. (Once Amended) The pharmaceutical composition according to any one of claims 23-28 [23-27 or 28], further comprising a therapeutically effect amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.